5-(苄氧基)-4-氟-2-甲基-1H-吲哚 | 649736-47-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 5-(苄氧基)-4-氟-2-甲基-1H-吲哚
• 英文名称: 5-benzyloxy-4-fluoro-2-methyl-1H-indole
• 英文别名: 4-Fluoro-2-methyl-5-(phenylmethoxy)-1h-indole；4-fluoro-2-methyl-5-phenylmethoxy-1H-indole
• CAS: 649736-47-0
• 化学式: C₁₆H₁₄FNO
• 分子量: 255.292
• InChiKey: YKJPLFDIYRGJGR-UHFFFAOYSA-N

物化性质

• 密度：
  1.232

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  25
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  1-(3-(苄氧基)-2-氟-6-硝基苯基)-2-丙酮 在 镍 肼 作用下， 以 甲醇 为溶剂， 反应 1.5h， 以80%的产率得到5-(苄氧基)-4-氟-2-甲基-1H-吲哚
  参考文献：
  名称：

  [EN] PROCESS FOR PREPARING CERTAIN PYRROLOTRIAZINE COMPOUNDS
  [FR] PROCEDE DE PREPARATION DE CERTAINS COMPOSES DE PYRROLOTRIAZINE

  摘要：

  公开号：

  WO2004009542A3

文献信息

• Novel inhibitors of kinases
  申请人：——

  公开号：US20040072832A1

  公开（公告）日：2004-04-15

  The present invention provides compounds of formula I, 1 and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供公式I的化合物及其药学上可接受的盐。公式I的化合物抑制生长因子受体的酪氨酸激酶活性，例如VEGFR-2和FGFR-1，因此使它们成为抗癌剂。公式I的化合物还可用于治疗与信号转导途径相关的其他疾病，这些途径通过生长因子受体运作。
• Process for preparing certain pyrrolotriazine compounds
  申请人：——

  公开号：US20040077858A1

  公开（公告）日：2004-04-22

  The present invention relates to a process for preparing certain pyrrolotriazine compounds of the formula 1 and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明涉及一种制备化合物式1及其药学上可接受的盐的吡咯并三嗪类化合物的方法。式I化合物抑制生长因子受体如VEGFR-2和FGFR-1的酪氨酸激酶活性，因此它们可作为抗癌剂使用。式I化合物还可用于治疗与通过生长因子受体进行信号转导途径相关的其他疾病。
• Inhibitors of kinases
  申请人：Bristol-Myers Squibb Company

  公开号：US07265113B2

  公开（公告）日：2007-09-04

  The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供了公式I的化合物，以及其药学上可接受的盐。公式I的化合物抑制生长因子受体的酪氨酸激酶活性，如VEGFR-2和FGFR-1，因此使它们有用作抗癌剂。公式I的化合物也用于治疗与通过生长因子受体操作的信号转导途径相关的其他疾病。
• Pyrrolo[2,1-f][1,2,4]triazine inhibitors of kinases
  申请人：Bhide Rajeev S.

  公开号：US06869952B2

  公开（公告）日：2005-03-22

  The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof. The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供I式化合物及其药学上可接受的盐。式I化合物抑制生长因子受体如VEGFR-2和FGFR-1的酪氨酸激酶活性，因此可用作抗癌剂。式I化合物也可用于治疗与通过生长因子受体进行信号传导途径相关的其他疾病。
• NOVEL INHIBITORS OF KINASES
  申请人：Bhide S. Rajeev

  公开号：US20070299075A1

  公开（公告）日：2007-12-27

  The present invention provides compounds of formula I, and pharmaceutically acceptable salts thereof The formula I compounds inhibit the tyrosine kinase activity of growth factor receptors such as VEGFR-2 and FGFR-1, thereby making them useful as anti-cancer agents. The formula I compounds are also useful for the treatment of other diseases associated with signal transduction pathways operating through growth factor receptors.

  本发明提供了I式化合物及其药学上可接受的盐。I式化合物抑制生长因子受体如VEGFR-2和FGFR-1的酪氨酸激酶活性，因此可用作抗癌剂。I式化合物还可用于治疗通过生长因子受体操作的信号转导途径引起的其他疾病。